Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Some members of the scientific community have concern that they’re coming out of the COVID pandemic—exposure to the virus, ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...